NVCR
Novocure Ltd
NASDAQ · Health Care
$10.14
+0.05 (+0.50%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 628.50M | 603.17M | 259.84M | 251.06M | 253.67M |
| Net Income | -175,117,423 | -151,253,052 | 44.23M | 43.96M | 45.64M |
| EPS | — | — | — | — | — |
| Profit Margin | -27.9% | -26.5% | 17.0% | 17.5% | 18.0% |
| Rev Growth | +4.2% | +4.2% | -5.2% | -1.9% | +7.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 366.41M | 366.41M | 402.18M | 319.88M | 342.35M |
| Total Equity | 201.34M | 201.34M | 369.73M | 378.69M | 362.47M |
| D/E Ratio | 1.82 | 1.82 | 1.09 | 0.84 | 0.94 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -136,651,612 | -124,586,402 | 71.86M | 70.91M | 75.95M |
| Free Cash Flow | — | — | 25.47M | 20.52M | 25.20M |